Novavax (NVAX) closed at $2.19 in the latest trading session, marking a -0.45% move from the prior day. This move lagged the S&P 500's daily gain of 1.29%. Meanwhile, the Dow gained 1.49%, and the Nasdaq, a tech-heavy index, added 1.46%.
Heading into today, shares of the vaccine maker had gained 5.77% over the past month, outpacing the Medical sector's gain of 2.06% and the S&P 500's gain of 4.57% in that time.
Investors will be hoping for strength from NVAX as it approaches its next earnings release. The company is expected to report EPS of -$0.12, up 25% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.87 million, down 24.42% from the year-ago period.
It is also important to note the recent changes to analyst estimates for NVAX. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.25% higher. NVAX is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 69, which puts it in the top 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Novavax, Inc. (NVAX): Get Free Report
Original post
Zacks Investment Research